IE
FDMT icon

Israel Englander’s 4D Molecular Therapeutics FDMT Stock Holding History

Israel Englander’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-50,000
Closed -$1.11M – 6507
2022
Q4 		$1.11M Buy
+50,000
New +$772K ﹤0.01% 4058

Other funds holding FDMT

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Israel Englander's FDMT Position: Q1 2026 in Review

Israel Englander sold out of 4D Molecular Therapeutics (FDMT) in Q1 2026, closing a stake of 96,364 shares — an estimated $723K sold.

Israel Englander first reported a position in FDMT in Q4 2020 and held it in 18 quarters. The position peaked at $14.5M in Q1 2021. 152 funds tracked by Wall St. Rank hold FDMT as of Q1 2026.

  • Israel Englander reported no remaining 4D Molecular Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Israel Englander sold 96,364 4D Molecular Therapeutics shares in Q1 2026, an estimated $723K.
  • Israel Englander first reported a position in 4D Molecular Therapeutics in Q4 2020 and held it in 18 quarters.
  • Israel Englander's 4D Molecular Therapeutics position peaked at $14.5M in Q1 2021.
  • 152 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.